Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 11/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 11/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31479832 | 0.90 | HCRTR1 (0.40) | HCRTR1HCRTR2GRIN2BSCN9AMEN1 | |
| SCHEMBL31479169 | 0.87 | HCRTR1 (0.39) | HCRTR1HCRTR2GRIN2BMEN1KMT2A | |
| SCHEMBL31479725 | 0.83 | HCRTR1 (0.36) | HCRTR1HCRTR2MEN1KMT2AKCNH2 | |
| SCHEMBL31479031 | 0.83 | GRIN2B (0.35) | HCRTR1HCRTR2GRIN2BSCN9A | |
| SCHEMBL31479143 | 0.79 | MAPT (0.40) | MEN1KMT2A | |
| SCHEMBL31479263 | 0.76 | HCRTR1 (0.41) | HCRTR1HCRTR2MEN1KMT2AKCNH2 | |
| SCHEMBL31479308 | 0.76 | HCRTR1 (0.39) | HCRTR1HCRTR2MEN1KMT2AKCNH2 | |
| SCHEMBL31479125 | 0.75 | HCRTR1 (0.39) | HCRTR1HCRTR2MEN1KMT2AKCNH2 | |
| SCHEMBL31479145 | 0.74 | HCRTR1 (0.41) | HCRTR1HCRTR2MEN1KMT2AKCNH2 | |
| SCHEMBL31479438 | 0.72 | IDO1 (0.43) | HCRTR1HCRTR2MEN1KMT2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025067111-A1 | MENIN-MLL INTERACTION INHIBITOR AND PREPARATION METHOD THEREFOR, AND APPLICATION | 苏州必扬医药科技有限公司 | 2025-04-03 | — | — | WO | disclosed |